β¨ Medicines Consent Notices
3616 NEW ZEALAND GAZETTE No. 114
Renewal of Provisional Consent to the Distribution of New Medicines
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Paclitaxel 6 mg/mL in 5 mL, 16.7 mL, 25 mL | Concentrate for infusion | Bristol-Caribbean Inc., Mayaguez, Puerto Rico | Taxol |
Note:
-
This medicine may only be distributed, supplied, or used under conditions to be imposed from time to time by the Director-General of Health.
-
This consent is effective from 29 July 1995.
Dated this 4th day of October 1995.
KAREN O. POUTASI, Director-General of Health, pursuant to delegation given by the Minister of Health on 25 June 1993.
go6736
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Sodium Bicarbonate 100% w/w (700 g) | Powder (sachet) | Mainland Pharmazeutische Fabrik, Frankfurt, Germany | Bi-Caps |
| Clotrimazole | Cream | Bayer AG, Leverkusen, Germany | Canesten HC |
| 150 mg/hydrocortisone, 150 mg (1%) clotrimazole in 15 g, | |||
| 300 mg/hydrocortisone, 300 mg (1%) clotrimazole in 30 g | |||
| Influenza virus A/Beijing/32/92 15.0 mcg, influenza virus A/Texas/36/91 15.0 mcg, | Suspension for injection | Evans Medical Limited, Speke, Liverpool, England | Fluvirin Inactivated Influenza |
| influenza virus B/Panama/45/90 15.0 mcg in 0.5 mL | (pre-filled syringe) | Vaccine | |
| Opium tincture 0.0838 mL, squill oxymel 1.67 mL in 5 mL | Syrup | Douglas Pharmaceuticals Limited, Mount Wellington, Auckland | Geeβs Linctus |
| Oestradiol delivery rate: 37.5 mcg/day, 50 mcg/day, 75 mcg/day, 100 mcg/day | Transdermal patch | Noven Pharmaceuticals Inc., Miami, Florida, United States of America | Menorest |
| Note: Not to be marketed as substitutable for any other oestradiol transdermal patch as if the two (2) products were bioequivalent. | |||
| Carbomer 940 2 mg/g, cetrimide 0.1 mg/g | Gel, ophthalmic | Ciba Vision AG., Hettlingen, Switzerland and Dr Mann Pharma Chem-Pharm Fabrik GmbH., Berlin, Germany | Viscotears Liquid Gel |
Dated this 5th day of October 1995.
KAREN O. POUTASI, Director-General of Health, pursuant to delegation given by the Minister of Health on 25 June 1993.
go6737
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1995, No 114
NZLII —
NZ Gazette 1995, No 114
β¨ LLM interpretation of page content
π₯ Renewal of Provisional Consent to the Distribution of New Medicines
π₯ Health & Social Welfare4 October 1995
Medicines Act, Provisional Consent, Paclitaxel, Taxol, Distribution
- KAREN O. POUTASI, Director-General of Health
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare5 October 1995
Medicines Act, Consent, Sodium Bicarbonate, Clotrimazole, Influenza Vaccine, Opium Tincture, Oestradiol Patch, Carbomer Gel
- KAREN O. POUTASI, Director-General of Health